================================================================================
                    EMPLOYEE STOCK OPTION SCHEME 2020
                    BIOPHARMA INDUSTRIES LIMITED
================================================================================

                    ESOP SCHEME DOCUMENT

================================================================================

BIOPHARMA INDUSTRIES LIMITED
CIN: U24230MH2012PLC234567

Employee Stock Option Scheme 2020
("BioPharma ESOP 2020" or "Scheme")

Approved by Board of Directors: December 15, 2019
Approved by Shareholders: January 15, 2020
Effective Date: April 1, 2020

================================================================================

ARTICLE 1: INTRODUCTION AND OBJECTIVES
-------------------------------------

1.1 NAME OF THE SCHEME

    This Scheme shall be called "BioPharma Industries Limited - Employee Stock
    Option Scheme 2020" or "BioPharma ESOP 2020".

1.2 OBJECTIVES

    The objectives of the Scheme are:

    (a) To attract, retain, and motivate talented employees including Key
        Technical Personnel critical for regulatory compliance

    (b) To align the interests of employees with those of shareholders

    (c) To reward employees for their contribution to Company's growth

    (d) To enable employees to participate in long-term wealth creation

    (e) To create a sense of ownership among employees

1.3 EFFECTIVE DATE

    The Scheme shall come into effect from April 1, 2020.

================================================================================

ARTICLE 2: DEFINITIONS
---------------------

2.1 "Act" means the Companies Act, 2013 and rules made thereunder.

2.2 "Board" means the Board of Directors of the Company.

2.3 "Committee" means the Nomination and Remuneration Committee constituted
    by the Board to administer this Scheme.

2.4 "Company" means BioPharma Industries Limited.

2.5 "Employee" means:
    (a) A permanent employee of the Company working in India or abroad; or
    (b) A Director of the Company (excluding Independent Directors); or
    (c) An employee of a subsidiary or holding company

    But does not include:
    (a) An employee who is a Promoter or belongs to the Promoter Group; or
    (b) A Director who holds more than 10% of the outstanding equity shares

2.6 "Exercise" means the process by which the Grantee converts the vested
    Options into equity shares by paying the Exercise Price.

2.7 "Exercise Period" means the period within which the Grantee must exercise
    the vested Options.

2.8 "Exercise Price" means the price per share payable by the Grantee to
    exercise the Options.

2.9 "Fair Market Value" means the value of the equity shares determined by
    the Committee based on a valuation report from a registered valuer.

2.10 "Grant" means the issue of Options to an Employee under this Scheme.

2.11 "Grant Date" means the date on which Options are granted to an Employee.

2.12 "Grantee" means an Employee who has been granted Options under the Scheme.

2.13 "Option" means a right but not an obligation granted to an Employee to
     apply for equity shares of the Company at the Exercise Price.

2.14 "Option Agreement" means the agreement entered into between the Company
     and the Grantee setting out the terms and conditions of the Grant.

2.15 "Vesting" means the process by which the Grantee acquires the right to
     exercise the Options.

2.16 "Vesting Period" means the period during which the Options vest in the
     Grantee.

================================================================================

ARTICLE 3: ADMINISTRATION
------------------------

3.1 NOMINATION AND REMUNERATION COMMITTEE

    The Scheme shall be administered by the Nomination and Remuneration
    Committee ("Committee") constituted by the Board.

3.2 COMPOSITION OF COMMITTEE

    The Committee shall consist of at least three Directors, of which at
    least half shall be Independent Directors.

    Current Composition:
    - Mr. Sandeep Kumar Agarwal (Chairman) - Independent Director
    - Mrs. Priya Suresh Menon - Independent Director
    - Dr. Ramesh Narayan Kulkarni - Managing Director

3.3 POWERS OF COMMITTEE

    The Committee shall have the authority to:
    (a) Determine eligibility of Employees
    (b) Determine the number of Options to be granted
    (c) Determine the Exercise Price
    (d) Determine the vesting schedule
    (e) Construe and interpret the Scheme
    (f) Establish procedures for administration
    (g) Modify or amend the terms of outstanding Options
    (h) Suspend or terminate the Scheme
    (i) Delegate powers to Company Secretary for administration

3.4 DECISIONS FINAL

    All decisions of the Committee shall be final, conclusive, and binding
    on all Grantees.

================================================================================

ARTICLE 4: SHARES AVAILABLE UNDER THE SCHEME
-------------------------------------------

4.1 MAXIMUM SHARES

    The maximum number of equity shares that may be issued under this Scheme
    shall be 15,00,000 (Fifteen Lakh) shares, representing 7.5% of the paid-up
    equity capital of the Company as on the date of shareholder approval.

4.2 SOURCE OF SHARES

    Shares for the Scheme shall be made available through fresh issue by the
    Company. Secondary acquisition from the market is not envisaged.

4.3 LAPSED OPTIONS

    Options that are forfeited, lapsed, or cancelled shall be available for
    future grants under the Scheme.

4.4 ADJUSTMENT FOR CORPORATE ACTIONS

    In case of any corporate action such as bonus issue, stock split, or
    rights issue, the Committee shall make appropriate adjustments to the
    number of Options and/or Exercise Price to prevent dilution or enlargement.

================================================================================

ARTICLE 5: ELIGIBILITY
---------------------

5.1 ELIGIBLE EMPLOYEES

    The following Employees shall be eligible for grant of Options:

    (a) All permanent employees who have completed at least one year of
        service with the Company

    (b) Directors of the Company (excluding Independent Directors and
        Promoter Directors)

    (c) Employees designated as "Key Technical Personnel" for regulatory
        purposes

    (d) Employees in managerial or supervisory positions

5.2 PRIORITY FOR KEY TECHNICAL PERSONNEL

    Given the critical nature of technical personnel for a pharmaceutical
    manufacturing company, the following employees shall be given priority
    in Option grants:

    - Technical Director (Approved Person under Drug License)
    - Head of Quality Assurance
    - Head of Quality Control
    - Head of Regulatory Affairs
    - R&D Head
    - Production Managers

5.3 INELIGIBLE PERSONS

    The following persons shall not be eligible:
    (a) Promoters or persons belonging to Promoter Group
    (b) Directors holding more than 10% of outstanding shares
    (c) Independent Directors
    (d) Employees on probation (unless specifically approved)
    (e) Employees under notice period

================================================================================

ARTICLE 6: GRANT OF OPTIONS
--------------------------

6.1 GRANT APPROVAL

    Options shall be granted by the Committee based on:
    (a) Employee's performance and potential
    (b) Criticality of role
    (c) Retention requirements
    (d) Company guidelines and limits
    (e) Regulatory compliance importance of the role

6.2 OPTION AGREEMENT

    Upon grant, the Grantee shall execute an Option Agreement specifying:
    (a) Number of Options granted
    (b) Grant Date
    (c) Exercise Price
    (d) Vesting schedule
    (e) Exercise Period
    (f) Other terms and conditions

6.3 MAXIMUM GRANT TO SINGLE EMPLOYEE

    No single Employee shall be granted Options exceeding 1% of the issued
    capital of the Company at the time of grant.

6.4 GRANT FREQUENCY

    The Committee may grant Options at any time during the year. Annual grant
    cycles are typically in April (after performance appraisal).

================================================================================

ARTICLE 7: EXERCISE PRICE
------------------------

7.1 DETERMINATION OF EXERCISE PRICE

    The Exercise Price shall be determined by the Committee, which may be:
    (a) Fair Market Value on the Grant Date; or
    (b) A discount to Fair Market Value (not exceeding 20%); or
    (c) Face value of shares (Rs. 10 per share)

7.2 FAIR MARKET VALUE

    Fair Market Value shall be determined based on a valuation report from
    a registered valuer using accepted valuation methodologies.

7.3 CURRENT EXERCISE PRICE

    For grants made in FY 2025-26:
    - Fair Market Value: Rs. 200 per share
    - Exercise Price: Rs. 200 per share (at FMV)

    (Based on valuation as of April 1, 2025)

================================================================================

ARTICLE 8: VESTING
-----------------

8.1 VESTING SCHEDULE

    Options shall vest over a period of 3 (three) years from the Grant Date
    as follows:

    End of Year    Vesting Percentage    Cumulative Vesting
    ------------------------------------------------------
    Year 1         33.33%                33.33%
    Year 2         33.33%                66.66%
    Year 3         33.34%                100.00%

8.2 CLIFF VESTING

    No Options shall vest before completion of one year from the Grant Date
    (cliff period).

8.3 CONDITIONS FOR VESTING

    Vesting is subject to:
    (a) Continued employment with the Company
    (b) Satisfactory performance ratings
    (c) No material breach of employment agreement
    (d) No regulatory violations attributable to the Employee

8.4 ACCELERATED VESTING

    The Committee may accelerate vesting in the following circumstances:
    (a) Death of the Grantee
    (b) Permanent disability
    (c) Retirement
    (d) Change of control of the Company
    (e) At Committee's discretion for exceptional performance

================================================================================

ARTICLE 9: EXERCISE OF OPTIONS
-----------------------------

9.1 EXERCISE PERIOD

    Vested Options may be exercised within a period of 3 (three) years from
    the date of vesting.

9.2 EXERCISE PROCESS

    To exercise Options, the Grantee shall:
    (a) Submit Exercise Notice to the Company
    (b) Pay the aggregate Exercise Price
    (c) Complete necessary documentation
    (d) Comply with tax deduction requirements

9.3 MINIMUM EXERCISE

    The minimum number of Options that may be exercised at any time shall be
    100 Options.

9.4 ALLOTMENT OF SHARES

    Upon valid exercise and receipt of Exercise Price, the Company shall
    allot equity shares within 30 days.

9.5 LOCK-IN PERIOD

    There shall be no lock-in period for shares acquired through exercise
    of Options.

================================================================================

ARTICLE 10: EFFECT OF TERMINATION OF EMPLOYMENT
----------------------------------------------

10.1 VOLUNTARY RESIGNATION

     If a Grantee resigns voluntarily:
     (a) Unvested Options shall be forfeited on the last working day
     (b) Vested but unexercised Options must be exercised within 90 days
         of last working day, failing which they shall lapse
     (c) Options exercised remain valid

10.2 TERMINATION FOR CAUSE

     If a Grantee is terminated for cause (misconduct, fraud, regulatory
     violation, etc.):
     (a) All unvested Options shall be forfeited immediately
     (b) All vested but unexercised Options shall be forfeited
     (c) Committee may require buyback of exercised shares at Exercise Price

10.3 TERMINATION WITHOUT CAUSE

     If a Grantee is terminated without cause (redundancy, restructuring):
     (a) Unvested Options shall be forfeited
     (b) Vested Options must be exercised within 180 days of termination

10.4 RETIREMENT

     Upon retirement (at superannuation age):
     (a) All outstanding Options shall vest immediately
     (b) Must be exercised within 1 year of retirement

10.5 DEATH

     Upon death of a Grantee:
     (a) All outstanding Options shall vest immediately
     (b) Legal heirs may exercise within 1 year of death

10.6 PERMANENT DISABILITY

     Upon permanent disability:
     (a) All outstanding Options shall vest immediately
     (b) Must be exercised within 1 year of disability

================================================================================

ARTICLE 11: CLAWBACK PROVISIONS
------------------------------

11.1 CLAWBACK FOR REGULATORY VIOLATIONS

     Given the regulated nature of pharmaceutical manufacturing, the Company
     reserves the right to clawback Options/Shares in the following cases:

     (a) If the Company's Drug Manufacturing License is suspended or cancelled
         due to acts or omissions of the Grantee

     (b) If regulatory prosecution is initiated against the Grantee for GMP
         violations

     (c) If material quality failure or product recall occurs due to Grantee's
         negligence

     (d) If pharmacovigilance violations occur under Grantee's responsibility

11.2 CLAWBACK FOR FRAUD OR MISCONDUCT

     Options/Shares may be clawed back if the Grantee is found guilty of:
     (a) Fraud or embezzlement
     (b) Material misstatement of financial information
     (c) Gross misconduct
     (d) Breach of confidentiality

11.3 CLAWBACK MECHANISM

     Clawback may be effected by:
     (a) Forfeiture of unvested Options
     (b) Forfeiture of vested but unexercised Options
     (c) Requirement to repay gains from exercise of Options
     (d) Buyback of shares at Exercise Price

================================================================================

ARTICLE 12: TAX IMPLICATIONS
---------------------------

12.1 TAX LIABILITY

     The Grantee shall be solely responsible for all tax obligations arising
     from the grant, vesting, exercise, or sale of Options/Shares.

12.2 TAX TREATMENT (FOR INFORMATION)

     Current tax treatment under Indian tax laws:

     (a) AT GRANT: No tax implication

     (b) AT VESTING: No tax implication

     (c) AT EXERCISE: The difference between Fair Market Value on exercise
         date and Exercise Price is taxed as perquisite (salary income).
         Company shall deduct TDS.

     (d) AT SALE: Capital gains tax on difference between sale price and
         Fair Market Value on exercise date.
         - Short-term (held < 24 months): Added to income, taxed at slab rate
         - Long-term (held > 24 months): 20% with indexation

12.3 TDS DEDUCTION

     The Company shall deduct TDS on perquisite value at exercise and deposit
     with Income Tax Department.

================================================================================

ARTICLE 13: RIGHTS OF GRANTEES
-----------------------------

13.1 NO SHAREHOLDER RIGHTS UNTIL EXERCISE

     Until Options are exercised and shares are allotted:
     (a) Grantee has no voting rights
     (b) Grantee has no dividend rights
     (c) Grantee has no right to participate in bonus or rights issues

13.2 NOT TRANSFERABLE

     Options are personal to the Grantee and are not transferable except:
     (a) By will or laws of inheritance
     (b) To legal heirs upon death

13.3 NO RIGHT TO EMPLOYMENT

     Grant of Options does not confer any right to continued employment with
     the Company.

================================================================================

ARTICLE 14: SCHEME AMENDMENT AND TERMINATION
-------------------------------------------

14.1 AMENDMENT

     The Board/Committee may amend the Scheme from time to time. However,
     amendments that adversely affect outstanding Options shall require
     consent of affected Grantees.

14.2 TERMINATION

     The Board may terminate the Scheme at any time. Termination shall not
     affect Options already granted.

14.3 SHAREHOLDER APPROVAL

     Certain amendments may require shareholder approval as per Companies Act.

================================================================================

ARTICLE 15: DISCLOSURES
----------------------

15.1 ANNUAL DISCLOSURES

     The Company shall make disclosures in the Directors' Report regarding:
     (a) Total Options granted, vested, exercised, lapsed during the year
     (b) Exercise Price
     (c) Employee-wise details for senior management
     (d) Diluted EPS

15.2 REGISTER OF OPTION HOLDERS

     The Company shall maintain a Register of Option Holders with:
     (a) Name and address of Grantee
     (b) Number of Options granted
     (c) Grant Date and Exercise Price
     (d) Vesting and exercise details

================================================================================

ARTICLE 16: CURRENT STATUS OF THE SCHEME
---------------------------------------

16.1 OPTIONS POOL

     Total Options authorized:        15,00,000
     Options granted to date:          8,50,000
     Options exercised:                2,20,000
     Options lapsed/forfeited:           80,000
     Options outstanding (unvested):   3,50,000
     Options outstanding (vested):     2,00,000
     Options available for grant:      6,50,000

16.2 KEY GRANTS TO TECHNICAL PERSONNEL

     Employee                Position           Options    Exercise Price
     -------------------------------------------------------------------
     Dr. Rajendra Patil      Technical Director   50,000   Rs. 150
     Mrs. Deepika Jain       Head - QA            40,000   Rs. 150
     Dr. Anita Shah          Head - QC            40,000   Rs. 150
     Mr. Suresh Sharma       Production Manager   30,000   Rs. 175
     Ms. Priya Desai         Regulatory Manager   25,000   Rs. 175
     [Other employees]       Various           5,65,000   Various

================================================================================

ARTICLE 17: APPLICABLE LAW
-------------------------

17.1 GOVERNING LAW

     This Scheme shall be governed by and construed in accordance with the
     laws of India.

17.2 COMPLIANCE

     The Scheme shall be implemented in compliance with:
     (a) Companies Act, 2013 and rules
     (b) Income Tax Act and rules
     (c) SEBI regulations (if applicable in future)
     (d) Other applicable laws

================================================================================

ANNEXURE: FORM OF OPTION AGREEMENT
---------------------------------

[Template of Option Agreement to be executed with each Grantee - available
separately]

================================================================================
                    END OF ESOP SCHEME DOCUMENT
================================================================================
